STOCK TITAN

[424B2] Inverse VIX Short-Term Futures ETNs due March 22, 2045 Prospectus Supplement

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
424B2
Rhea-AI Filing Summary

JPMorgan Chase Financial Company LLC is offering Auto Callable Yield Notes due July 20, 2026 that are fully and unconditionally guaranteed by JPMorgan Chase & Co. The notes pay a minimum interest rate of 22.35% per annum (≈1.8625% monthly) on $1,000 denominations, provided the notes have not been automatically called. Payments are tied to the individual performance of three reference stocks—Broadcom Inc. (AVGO), Moderna Inc. (MRNA) and NVIDIA Corp. (NVDA)—rather than to a basket.

Automatic call feature: Beginning January 15, 2026 and on each monthly Review Date thereafter (except the final one), the notes are called if the closing price of each reference stock is at or above its Initial Value. Upon a call, investors receive $1,000 principal plus the scheduled interest for that month; no further payments are made.

Principal risk: If the notes are not called and the Final Value of any reference stock is below 60% of its Initial Value (the Trigger Value), repayment of principal is reduced by the percentage decline of the worst–performing stock (the “Least Performing Reference Stock”). Investors can lose more than 40% and up to 100% of principal.

  • Pricing date: on or about July 15, 2025; settlement July 18, 2025
  • Estimated value: approximately $955.70 per $1,000 note today; final estimated value will not be lower than $920.00
  • Fees: selling commissions up to $15 per $1,000; original issue price embeds hedging and structuring costs
  • Credit exposure: unsecured, unsubordinated obligations of JPMorgan Financial; subject to JPMorgan Chase & Co. credit risk
  • Liquidity: not listed; resale depends on JPMS bid, which is expected to be lower than issue price and may be unavailable
  • CUSIP: 48136FMR0; minimum purchase $1,000

Illustrative scenarios highlight (1) an 11.175% total return if called on the first Review Date, (2) a 22.35% total return if held to maturity with all stocks above the Trigger, and (3) a −27.65% total return when the worst stock falls 50% below its Initial Value at final valuation.

Key risks disclosed include potential loss of principal, limited upside to interest only, exposure to the worst-performing stock, early-call reinvestment risk, lack of dividend entitlement, secondary-market discounting, and conflicts of interest arising from JPMorgan’s multiple roles. The notes are not FDIC-insured.

JPMorgan Chase Financial Company LLC offre Note con Cedola Autocallabile in scadenza il 20 luglio 2026, garantite in modo pieno e incondizionato da JPMorgan Chase & Co. Le note corrispondono un tasso di interesse minimo del 22,35% annuo (circa 1,8625% mensile) su tagli da $1.000, a condizione che le note non siano state richiamate automaticamente. I pagamenti dipendono dalla performance individuale di tre azioni di riferimento — Broadcom Inc. (AVGO), Moderna Inc. (MRNA) e NVIDIA Corp. (NVDA) — e non da un paniere.

Caratteristica di richiamo automatico: A partire dal 15 gennaio 2026 e in ogni data di revisione mensile successiva (tranne l’ultima), le note vengono richiamate se il prezzo di chiusura di ciascuna azione di riferimento è pari o superiore al suo Valore Iniziale. In caso di richiamo, gli investitori ricevono $1.000 di capitale più l’interesse previsto per quel mese; non sono previsti ulteriori pagamenti.

Rischio sul capitale: Se le note non vengono richiamate e il Valore Finale di qualunque azione di riferimento è inferiore al 60% del Valore Iniziale (il Valore di Attivazione), il rimborso del capitale viene ridotto in proporzione al calo della peggiore azione (la “Azione di Riferimento meno performante”). Gli investitori possono perdere più del 40% e fino al 100% del capitale investito.

  • Data di prezzo: circa 15 luglio 2025; regolamento 18 luglio 2025
  • Valore stimato: circa $955,70 per ogni nota da $1.000 oggi; il valore stimato finale non sarà inferiore a $920,00
  • Commissioni: commissioni di vendita fino a $15 per ogni $1.000; il prezzo di emissione originale include costi di copertura e strutturazione
  • Esposizione creditizia: obbligazioni non garantite e non subordinate di JPMorgan Financial; soggette al rischio di credito di JPMorgan Chase & Co.
  • Liquidità: non quotate; la rivendita dipende dall’offerta di JPMS, che potrebbe essere inferiore al prezzo di emissione e talvolta non disponibile
  • CUSIP: 48136FMR0; acquisto minimo $1.000

Scenari illustrativi mostrano (1) un rendimento totale dell’11,175% se richiamate alla prima data di revisione, (2) un rendimento totale del 22,35% se detenute fino a scadenza con tutte le azioni sopra il Valore di Attivazione, e (3) un rendimento totale di −27,65% se la peggior azione scende del 50% sotto il Valore Iniziale alla valutazione finale.

Principali rischi includono possibile perdita del capitale, rendimento limitato all’interesse, esposizione alla peggiore azione, rischio di reinvestimento in caso di richiamo anticipato, assenza di diritto ai dividendi, sconti sul mercato secondario e conflitti di interesse derivanti dai molteplici ruoli di JPMorgan. Le note non sono assicurate dalla FDIC.

JPMorgan Chase Financial Company LLC ofrece Notas con Rendimiento Autollamables con vencimiento el 20 de julio de 2026, garantizadas total e incondicionalmente por JPMorgan Chase & Co. Las notas pagan una tasa mínima de interés del 22,35% anual (aproximadamente 1,8625% mensual) sobre denominaciones de $1,000, siempre que las notas no hayan sido llamadas automáticamente. Los pagos están vinculados al desempeño individual de tres acciones de referencia — Broadcom Inc. (AVGO), Moderna Inc. (MRNA) y NVIDIA Corp. (NVDA) — y no a una canasta.

Función de llamada automática: A partir del 15 de enero de 2026 y en cada fecha de revisión mensual posterior (excepto la última), las notas se llaman si el precio de cierre de cada acción de referencia está en o por encima de su Valor Inicial. Al ser llamadas, los inversionistas reciben $1,000 de principal más el interés programado para ese mes; no se realizan pagos adicionales.

Riesgo de principal: Si las notas no son llamadas y el Valor Final de cualquier acción de referencia está por debajo del 60% de su Valor Inicial (el Valor de Activación), el reembolso del principal se reduce según el porcentaje de caída de la acción con peor desempeño (la “Acción de Referencia con menor rendimiento”). Los inversionistas pueden perder más del 40% y hasta el 100% del principal.

  • Fecha de fijación de precio: alrededor del 15 de julio de 2025; liquidación el 18 de julio de 2025
  • Valor estimado: aproximadamente $955.70 por cada nota de $1,000 hoy; el valor estimado final no será inferior a $920.00
  • Comisiones: comisiones de venta hasta $15 por cada $1,000; el precio original de emisión incluye costos de cobertura y estructuración
  • Exposición crediticia: obligaciones no garantizadas y no subordinadas de JPMorgan Financial; sujetas al riesgo crediticio de JPMorgan Chase & Co.
  • Liquidez: no cotizadas; la reventa depende de la oferta de JPMS, que se espera sea inferior al precio de emisión y puede no estar disponible
  • CUSIP: 48136FMR0; compra mínima $1,000

Los escenarios ilustrativos muestran (1) un rendimiento total del 11,175% si se llama en la primera fecha de revisión, (2) un rendimiento total del 22,35% si se mantiene hasta el vencimiento con todas las acciones por encima del Valor de Activación, y (3) un rendimiento total de −27,65% si la peor acción cae un 50% por debajo de su Valor Inicial en la valoración final.

Riesgos clave incluyen posible pérdida del principal, rendimiento limitado solo al interés, exposición a la acción con peor desempeño, riesgo de reinversión por llamada anticipada, ausencia de derecho a dividendos, descuentos en el mercado secundario y conflictos de interés derivados de los múltiples roles de JPMorgan. Las notas no están aseguradas por la FDIC.

JPMorgan Chase Financial Company LLC2026년 7월 20일 만기 자동 콜 가능 수익 노트를 제공하며, 이는 JPMorgan Chase & Co.의 전면적이고 무조건적인 보증을 받습니다. 이 노트는 $1,000 단위로 최소 연이율 22.35% (월 약 1.8625%)를 지급하며, 노트가 자동으로 콜되지 않은 경우에 한합니다. 지급은 Broadcom Inc. (AVGO), Moderna Inc. (MRNA), NVIDIA Corp. (NVDA) 등 세 개 개별 주식의 성과에 연동되며, 바스켓이 아닌 개별 주식 기준입니다.

자동 콜 기능: 2026년 1월 15일부터 시작하여 이후 매월 검토일(마지막 검토일 제외)에 각 참조 주식의 종가가 초기 가치 이상이면 노트가 콜됩니다. 콜 시 투자자는 $1,000 원금과 해당 월의 예정 이자를 받으며, 추가 지급은 없습니다.

원금 위험: 노트가 콜되지 않고 최종 가치가 어떤 참조 주식이라도 초기 가치의 60% 미만(트리거 가치)인 경우, 원금 상환은 성과가 가장 저조한 주식(“최저 성과 참조 주식”)의 하락률만큼 감소합니다. 투자자는 최대 40% 이상, 최대 100%까지 원금 손실이 발생할 수 있습니다.

  • 가격 결정일: 2025년 7월 15일경; 결제일 2025년 7월 18일
  • 예상 가치: 현재 $1,000 노트당 약 $955.70; 최종 예상 가치는 $920.00 이하로 떨어지지 않음
  • 수수료: $1,000당 최대 $15 판매 수수료; 최초 발행가에는 헤지 및 구조화 비용 포함
  • 신용 노출: JPMorgan Financial의 무담보 비후순위 채무; JPMorgan Chase & Co.의 신용 위험에 노출
  • 유동성: 상장되지 않음; 재판매는 JPMS 입찰에 따라 결정되며, 발행가보다 낮거나 입찰이 없을 수 있음
  • CUSIP: 48136FMR0; 최소 구매 $1,000

예시 시나리오는 (1) 첫 검토일에 콜될 경우 총 수익률 11.175%, (2) 모든 주식이 트리거 이상일 경우 만기까지 보유 시 총 수익률 22.35%, (3) 최악의 주식이 최종 평가 시 초기 가치 대비 50% 하락할 경우 총 수익률 −27.65%를 보여줍니다.

주요 위험으로는 원금 손실 가능성, 이자만 지급되어 상승 제한, 최저 성과 주식에 대한 노출, 조기 콜 시 재투자 위험, 배당금 권리 없음, 2차 시장 할인, JPMorgan의 다중 역할로 인한 이해 상충 등이 있으며, 노트는 FDIC 보험 대상이 아닙니다.

JPMorgan Chase Financial Company LLC propose des Notes à Rendement Auto-Rappelables arrivant à échéance le 20 juillet 2026, entièrement et inconditionnellement garanties par JPMorgan Chase & Co. Les notes versent un taux d’intérêt minimum de 22,35% par an (environ 1,8625% par mois) sur des coupures de 1 000 $, à condition que les notes n’aient pas été rappelées automatiquement. Les paiements sont liés à la performance individuelle de trois actions de référence — Broadcom Inc. (AVGO), Moderna Inc. (MRNA) et NVIDIA Corp. (NVDA) — et non à un panier.

Fonction de rappel automatique : À partir du 15 janvier 2026 et à chaque date de révision mensuelle suivante (sauf la dernière), les notes sont rappelées si le cours de clôture de chaque action de référence est égal ou supérieur à sa Valeur Initiale. En cas de rappel, les investisseurs reçoivent 1 000 $ de principal plus l’intérêt prévu pour ce mois ; aucun paiement supplémentaire n’est effectué.

Risque sur le principal : Si les notes ne sont pas rappelées et que la Valeur Finale de n’importe quelle action de référence est inférieure à 60 % de sa Valeur Initiale (la Valeur Déclencheur), le remboursement du principal est réduit du pourcentage de baisse de l’action la moins performante (l’« Action de Référence la Moins Performante »). Les investisseurs peuvent perdre plus de 40 % et jusqu’à 100 % du principal.

  • Date de fixation du prix : vers le 15 juillet 2025 ; règlement le 18 juillet 2025
  • Valeur estimée : environ 955,70 $ par note de 1 000 $ aujourd’hui ; la valeur estimée finale ne sera pas inférieure à 920,00 $
  • Frais : commissions de vente jusqu’à 15 $ par tranche de 1 000 $ ; le prix d’émission initial inclut les coûts de couverture et de structuration
  • Exposition au crédit : obligations non garanties et non subordonnées de JPMorgan Financial ; soumises au risque de crédit de JPMorgan Chase & Co.
  • Liquidité : non cotées ; la revente dépend de l’offre de JPMS, qui devrait être inférieure au prix d’émission et peut ne pas être disponible
  • CUSIP : 48136FMR0 ; achat minimum 1 000 $

Les scénarios illustratifs mettent en évidence (1) un rendement total de 11,175 % si rappelé à la première date de révision, (2) un rendement total de 22,35 % si conservé jusqu’à l’échéance avec toutes les actions au-dessus du seuil, et (3) un rendement total de −27,65 % si la pire action chute de 50 % en dessous de sa Valeur Initiale à la valorisation finale.

Principaux risques divulgués incluent la perte potentielle du principal, un gain limité aux seuls intérêts, l’exposition à la pire action, le risque de réinvestissement en cas de rappel anticipé, l’absence de droit aux dividendes, les décotes sur le marché secondaire et les conflits d’intérêts liés aux multiples rôles de JPMorgan. Les notes ne sont pas assurées par la FDIC.

JPMorgan Chase Financial Company LLC bietet Auto Callable Yield Notes mit Fälligkeit am 20. Juli 2026 an, die von JPMorgan Chase & Co. vollständig und bedingungslos garantiert werden. Die Notes zahlen einen Mindestzinssatz von 22,35% pro Jahr (ca. 1,8625% monatlich) auf Stückelungen von $1.000, vorausgesetzt, die Notes wurden nicht automatisch zurückgerufen. Die Zahlungen sind an die individuelle Performance von drei Referenzaktien – Broadcom Inc. (AVGO), Moderna Inc. (MRNA) und NVIDIA Corp. (NVDA) – gebunden und nicht an einen Korb.

Automatische Rückruf-Funktion: Ab dem 15. Januar 2026 und an jedem folgenden monatlichen Überprüfungstermin (außer dem letzten) werden die Notes zurückgerufen, wenn der Schlusskurs jeder Referenzaktie auf oder über ihrem Anfangswert liegt. Bei Rückruf erhalten Anleger $1.000 Kapital zuzüglich der für diesen Monat vorgesehenen Zinsen; weitere Zahlungen erfolgen nicht.

Kapitalrisiko: Wenn die Notes nicht zurückgerufen werden und der Endwert irgendeiner Referenzaktie unter 60% ihres Anfangswerts (dem Auslösewert) liegt, wird die Rückzahlung des Kapitals um den prozentualen Rückgang der am schlechtesten performenden Aktie (die „am schlechtesten performende Referenzaktie“) reduziert. Anleger können mehr als 40% und bis zu 100% des Kapitals verlieren.

  • Preisfeststellung: ca. 15. Juli 2025; Abrechnung am 18. Juli 2025
  • Geschätzter Wert: heute etwa $955,70 pro $1.000 Note; der endgültige geschätzte Wert wird nicht unter $920,00 liegen
  • Gebühren: Verkaufskommissionen bis zu $15 pro $1.000; der ursprüngliche Ausgabepreis beinhaltet Absicherungs- und Strukturierungskosten
  • Kreditrisiko: unbesicherte, nicht nachrangige Verbindlichkeiten von JPMorgan Financial; unterliegen dem Kreditrisiko von JPMorgan Chase & Co.
  • Liquidität: nicht börsennotiert; Weiterverkauf hängt vom Gebot von JPMS ab, das voraussichtlich unter dem Ausgabepreis liegt und möglicherweise nicht verfügbar ist
  • CUSIP: 48136FMR0; Mindestkauf $1.000

Beispielszenarien zeigen (1) eine Gesamtrendite von 11,175%, wenn bei der ersten Überprüfung zurückgerufen, (2) eine Gesamtrendite von 22,35%, wenn bis zur Fälligkeit gehalten und alle Aktien über dem Auslösewert liegen, und (3) eine Gesamtrendite von −27,65%, wenn die schlechteste Aktie bei der Endbewertung 50% unter ihrem Anfangswert liegt.

Wesentliche Risiken umfassen potenziellen Kapitalverlust, begrenztes Aufwärtspotenzial nur auf Zinsen, Risiko durch die am schlechtesten performende Aktie, Reinvestitionsrisiko bei vorzeitigem Rückruf, fehlende Dividendenansprüche, Abschläge am Sekundärmarkt und Interessenkonflikte durch die vielfältigen Rollen von JPMorgan. Die Notes sind nicht FDIC-versichert.

Positive
  • Attractive fixed income: minimum 22.35% annual coupon until call or maturity, well above conventional debt yields.
  • Automatic call mechanism can deliver double-digit returns in as little as six months if all reference stocks appreciate modestly.
  • 40% downside buffer: principal is protected unless any stock falls more than 40% from its Initial Value by final valuation.
Negative
  • Principal loss risk: if any stock closes below 60% of its Initial Value at final review, investors lose 1% principal per 1% decline with no floor.
  • Upside capped: returns are limited to cumulative interest; no participation in equity appreciation beyond call trigger.
  • Credit & liquidity risk: unsecured claim on JPMorgan; notes are unlisted and may trade at a significant discount, or not at all.
  • Estimated value discount: fair value ($≈955.70) is below issue price, reflecting selling commissions and hedging costs.

Insights

TL;DR High 22.35% coupon offsets significant principal-at-risk tied to worst stock; upside capped, downside open below 60% barrier.

The structure targets yield-seeking investors comfortable exchanging equity upside for fixed, above-market income. Monthly interest of at least 1.8625% continues until an automatic call, which can occur as early as six months after issue if all three stocks meet or exceed initial prices. Early call locks in gains but creates reinvestment risk at lower yields.

Principal protection is conditional: if any stock is below 60% of its Initial Value on the final Review Date, repayment is proportionally reduced, leading to potentially steep losses. Historical volatility of MRNA and NVDA in particular raises the probability of breaching the 40% buffer.

The embedded derivative value is marked at $955.70, indicating an initial 4.4% premium over estimated fair value, driven by distribution costs and hedging. Investors should also weigh JPMorgan credit exposure and limited secondary liquidity.

Overall, the note offers attractive cash flow in a low-rate environment but is best suited for investors with a constructive view on all three equities and tolerance for significant downside.

JPMorgan Chase Financial Company LLC offre Note con Cedola Autocallabile in scadenza il 20 luglio 2026, garantite in modo pieno e incondizionato da JPMorgan Chase & Co. Le note corrispondono un tasso di interesse minimo del 22,35% annuo (circa 1,8625% mensile) su tagli da $1.000, a condizione che le note non siano state richiamate automaticamente. I pagamenti dipendono dalla performance individuale di tre azioni di riferimento — Broadcom Inc. (AVGO), Moderna Inc. (MRNA) e NVIDIA Corp. (NVDA) — e non da un paniere.

Caratteristica di richiamo automatico: A partire dal 15 gennaio 2026 e in ogni data di revisione mensile successiva (tranne l’ultima), le note vengono richiamate se il prezzo di chiusura di ciascuna azione di riferimento è pari o superiore al suo Valore Iniziale. In caso di richiamo, gli investitori ricevono $1.000 di capitale più l’interesse previsto per quel mese; non sono previsti ulteriori pagamenti.

Rischio sul capitale: Se le note non vengono richiamate e il Valore Finale di qualunque azione di riferimento è inferiore al 60% del Valore Iniziale (il Valore di Attivazione), il rimborso del capitale viene ridotto in proporzione al calo della peggiore azione (la “Azione di Riferimento meno performante”). Gli investitori possono perdere più del 40% e fino al 100% del capitale investito.

  • Data di prezzo: circa 15 luglio 2025; regolamento 18 luglio 2025
  • Valore stimato: circa $955,70 per ogni nota da $1.000 oggi; il valore stimato finale non sarà inferiore a $920,00
  • Commissioni: commissioni di vendita fino a $15 per ogni $1.000; il prezzo di emissione originale include costi di copertura e strutturazione
  • Esposizione creditizia: obbligazioni non garantite e non subordinate di JPMorgan Financial; soggette al rischio di credito di JPMorgan Chase & Co.
  • Liquidità: non quotate; la rivendita dipende dall’offerta di JPMS, che potrebbe essere inferiore al prezzo di emissione e talvolta non disponibile
  • CUSIP: 48136FMR0; acquisto minimo $1.000

Scenari illustrativi mostrano (1) un rendimento totale dell’11,175% se richiamate alla prima data di revisione, (2) un rendimento totale del 22,35% se detenute fino a scadenza con tutte le azioni sopra il Valore di Attivazione, e (3) un rendimento totale di −27,65% se la peggior azione scende del 50% sotto il Valore Iniziale alla valutazione finale.

Principali rischi includono possibile perdita del capitale, rendimento limitato all’interesse, esposizione alla peggiore azione, rischio di reinvestimento in caso di richiamo anticipato, assenza di diritto ai dividendi, sconti sul mercato secondario e conflitti di interesse derivanti dai molteplici ruoli di JPMorgan. Le note non sono assicurate dalla FDIC.

JPMorgan Chase Financial Company LLC ofrece Notas con Rendimiento Autollamables con vencimiento el 20 de julio de 2026, garantizadas total e incondicionalmente por JPMorgan Chase & Co. Las notas pagan una tasa mínima de interés del 22,35% anual (aproximadamente 1,8625% mensual) sobre denominaciones de $1,000, siempre que las notas no hayan sido llamadas automáticamente. Los pagos están vinculados al desempeño individual de tres acciones de referencia — Broadcom Inc. (AVGO), Moderna Inc. (MRNA) y NVIDIA Corp. (NVDA) — y no a una canasta.

Función de llamada automática: A partir del 15 de enero de 2026 y en cada fecha de revisión mensual posterior (excepto la última), las notas se llaman si el precio de cierre de cada acción de referencia está en o por encima de su Valor Inicial. Al ser llamadas, los inversionistas reciben $1,000 de principal más el interés programado para ese mes; no se realizan pagos adicionales.

Riesgo de principal: Si las notas no son llamadas y el Valor Final de cualquier acción de referencia está por debajo del 60% de su Valor Inicial (el Valor de Activación), el reembolso del principal se reduce según el porcentaje de caída de la acción con peor desempeño (la “Acción de Referencia con menor rendimiento”). Los inversionistas pueden perder más del 40% y hasta el 100% del principal.

  • Fecha de fijación de precio: alrededor del 15 de julio de 2025; liquidación el 18 de julio de 2025
  • Valor estimado: aproximadamente $955.70 por cada nota de $1,000 hoy; el valor estimado final no será inferior a $920.00
  • Comisiones: comisiones de venta hasta $15 por cada $1,000; el precio original de emisión incluye costos de cobertura y estructuración
  • Exposición crediticia: obligaciones no garantizadas y no subordinadas de JPMorgan Financial; sujetas al riesgo crediticio de JPMorgan Chase & Co.
  • Liquidez: no cotizadas; la reventa depende de la oferta de JPMS, que se espera sea inferior al precio de emisión y puede no estar disponible
  • CUSIP: 48136FMR0; compra mínima $1,000

Los escenarios ilustrativos muestran (1) un rendimiento total del 11,175% si se llama en la primera fecha de revisión, (2) un rendimiento total del 22,35% si se mantiene hasta el vencimiento con todas las acciones por encima del Valor de Activación, y (3) un rendimiento total de −27,65% si la peor acción cae un 50% por debajo de su Valor Inicial en la valoración final.

Riesgos clave incluyen posible pérdida del principal, rendimiento limitado solo al interés, exposición a la acción con peor desempeño, riesgo de reinversión por llamada anticipada, ausencia de derecho a dividendos, descuentos en el mercado secundario y conflictos de interés derivados de los múltiples roles de JPMorgan. Las notas no están aseguradas por la FDIC.

JPMorgan Chase Financial Company LLC2026년 7월 20일 만기 자동 콜 가능 수익 노트를 제공하며, 이는 JPMorgan Chase & Co.의 전면적이고 무조건적인 보증을 받습니다. 이 노트는 $1,000 단위로 최소 연이율 22.35% (월 약 1.8625%)를 지급하며, 노트가 자동으로 콜되지 않은 경우에 한합니다. 지급은 Broadcom Inc. (AVGO), Moderna Inc. (MRNA), NVIDIA Corp. (NVDA) 등 세 개 개별 주식의 성과에 연동되며, 바스켓이 아닌 개별 주식 기준입니다.

자동 콜 기능: 2026년 1월 15일부터 시작하여 이후 매월 검토일(마지막 검토일 제외)에 각 참조 주식의 종가가 초기 가치 이상이면 노트가 콜됩니다. 콜 시 투자자는 $1,000 원금과 해당 월의 예정 이자를 받으며, 추가 지급은 없습니다.

원금 위험: 노트가 콜되지 않고 최종 가치가 어떤 참조 주식이라도 초기 가치의 60% 미만(트리거 가치)인 경우, 원금 상환은 성과가 가장 저조한 주식(“최저 성과 참조 주식”)의 하락률만큼 감소합니다. 투자자는 최대 40% 이상, 최대 100%까지 원금 손실이 발생할 수 있습니다.

  • 가격 결정일: 2025년 7월 15일경; 결제일 2025년 7월 18일
  • 예상 가치: 현재 $1,000 노트당 약 $955.70; 최종 예상 가치는 $920.00 이하로 떨어지지 않음
  • 수수료: $1,000당 최대 $15 판매 수수료; 최초 발행가에는 헤지 및 구조화 비용 포함
  • 신용 노출: JPMorgan Financial의 무담보 비후순위 채무; JPMorgan Chase & Co.의 신용 위험에 노출
  • 유동성: 상장되지 않음; 재판매는 JPMS 입찰에 따라 결정되며, 발행가보다 낮거나 입찰이 없을 수 있음
  • CUSIP: 48136FMR0; 최소 구매 $1,000

예시 시나리오는 (1) 첫 검토일에 콜될 경우 총 수익률 11.175%, (2) 모든 주식이 트리거 이상일 경우 만기까지 보유 시 총 수익률 22.35%, (3) 최악의 주식이 최종 평가 시 초기 가치 대비 50% 하락할 경우 총 수익률 −27.65%를 보여줍니다.

주요 위험으로는 원금 손실 가능성, 이자만 지급되어 상승 제한, 최저 성과 주식에 대한 노출, 조기 콜 시 재투자 위험, 배당금 권리 없음, 2차 시장 할인, JPMorgan의 다중 역할로 인한 이해 상충 등이 있으며, 노트는 FDIC 보험 대상이 아닙니다.

JPMorgan Chase Financial Company LLC propose des Notes à Rendement Auto-Rappelables arrivant à échéance le 20 juillet 2026, entièrement et inconditionnellement garanties par JPMorgan Chase & Co. Les notes versent un taux d’intérêt minimum de 22,35% par an (environ 1,8625% par mois) sur des coupures de 1 000 $, à condition que les notes n’aient pas été rappelées automatiquement. Les paiements sont liés à la performance individuelle de trois actions de référence — Broadcom Inc. (AVGO), Moderna Inc. (MRNA) et NVIDIA Corp. (NVDA) — et non à un panier.

Fonction de rappel automatique : À partir du 15 janvier 2026 et à chaque date de révision mensuelle suivante (sauf la dernière), les notes sont rappelées si le cours de clôture de chaque action de référence est égal ou supérieur à sa Valeur Initiale. En cas de rappel, les investisseurs reçoivent 1 000 $ de principal plus l’intérêt prévu pour ce mois ; aucun paiement supplémentaire n’est effectué.

Risque sur le principal : Si les notes ne sont pas rappelées et que la Valeur Finale de n’importe quelle action de référence est inférieure à 60 % de sa Valeur Initiale (la Valeur Déclencheur), le remboursement du principal est réduit du pourcentage de baisse de l’action la moins performante (l’« Action de Référence la Moins Performante »). Les investisseurs peuvent perdre plus de 40 % et jusqu’à 100 % du principal.

  • Date de fixation du prix : vers le 15 juillet 2025 ; règlement le 18 juillet 2025
  • Valeur estimée : environ 955,70 $ par note de 1 000 $ aujourd’hui ; la valeur estimée finale ne sera pas inférieure à 920,00 $
  • Frais : commissions de vente jusqu’à 15 $ par tranche de 1 000 $ ; le prix d’émission initial inclut les coûts de couverture et de structuration
  • Exposition au crédit : obligations non garanties et non subordonnées de JPMorgan Financial ; soumises au risque de crédit de JPMorgan Chase & Co.
  • Liquidité : non cotées ; la revente dépend de l’offre de JPMS, qui devrait être inférieure au prix d’émission et peut ne pas être disponible
  • CUSIP : 48136FMR0 ; achat minimum 1 000 $

Les scénarios illustratifs mettent en évidence (1) un rendement total de 11,175 % si rappelé à la première date de révision, (2) un rendement total de 22,35 % si conservé jusqu’à l’échéance avec toutes les actions au-dessus du seuil, et (3) un rendement total de −27,65 % si la pire action chute de 50 % en dessous de sa Valeur Initiale à la valorisation finale.

Principaux risques divulgués incluent la perte potentielle du principal, un gain limité aux seuls intérêts, l’exposition à la pire action, le risque de réinvestissement en cas de rappel anticipé, l’absence de droit aux dividendes, les décotes sur le marché secondaire et les conflits d’intérêts liés aux multiples rôles de JPMorgan. Les notes ne sont pas assurées par la FDIC.

JPMorgan Chase Financial Company LLC bietet Auto Callable Yield Notes mit Fälligkeit am 20. Juli 2026 an, die von JPMorgan Chase & Co. vollständig und bedingungslos garantiert werden. Die Notes zahlen einen Mindestzinssatz von 22,35% pro Jahr (ca. 1,8625% monatlich) auf Stückelungen von $1.000, vorausgesetzt, die Notes wurden nicht automatisch zurückgerufen. Die Zahlungen sind an die individuelle Performance von drei Referenzaktien – Broadcom Inc. (AVGO), Moderna Inc. (MRNA) und NVIDIA Corp. (NVDA) – gebunden und nicht an einen Korb.

Automatische Rückruf-Funktion: Ab dem 15. Januar 2026 und an jedem folgenden monatlichen Überprüfungstermin (außer dem letzten) werden die Notes zurückgerufen, wenn der Schlusskurs jeder Referenzaktie auf oder über ihrem Anfangswert liegt. Bei Rückruf erhalten Anleger $1.000 Kapital zuzüglich der für diesen Monat vorgesehenen Zinsen; weitere Zahlungen erfolgen nicht.

Kapitalrisiko: Wenn die Notes nicht zurückgerufen werden und der Endwert irgendeiner Referenzaktie unter 60% ihres Anfangswerts (dem Auslösewert) liegt, wird die Rückzahlung des Kapitals um den prozentualen Rückgang der am schlechtesten performenden Aktie (die „am schlechtesten performende Referenzaktie“) reduziert. Anleger können mehr als 40% und bis zu 100% des Kapitals verlieren.

  • Preisfeststellung: ca. 15. Juli 2025; Abrechnung am 18. Juli 2025
  • Geschätzter Wert: heute etwa $955,70 pro $1.000 Note; der endgültige geschätzte Wert wird nicht unter $920,00 liegen
  • Gebühren: Verkaufskommissionen bis zu $15 pro $1.000; der ursprüngliche Ausgabepreis beinhaltet Absicherungs- und Strukturierungskosten
  • Kreditrisiko: unbesicherte, nicht nachrangige Verbindlichkeiten von JPMorgan Financial; unterliegen dem Kreditrisiko von JPMorgan Chase & Co.
  • Liquidität: nicht börsennotiert; Weiterverkauf hängt vom Gebot von JPMS ab, das voraussichtlich unter dem Ausgabepreis liegt und möglicherweise nicht verfügbar ist
  • CUSIP: 48136FMR0; Mindestkauf $1.000

Beispielszenarien zeigen (1) eine Gesamtrendite von 11,175%, wenn bei der ersten Überprüfung zurückgerufen, (2) eine Gesamtrendite von 22,35%, wenn bis zur Fälligkeit gehalten und alle Aktien über dem Auslösewert liegen, und (3) eine Gesamtrendite von −27,65%, wenn die schlechteste Aktie bei der Endbewertung 50% unter ihrem Anfangswert liegt.

Wesentliche Risiken umfassen potenziellen Kapitalverlust, begrenztes Aufwärtspotenzial nur auf Zinsen, Risiko durch die am schlechtesten performende Aktie, Reinvestitionsrisiko bei vorzeitigem Rückruf, fehlende Dividendenansprüche, Abschläge am Sekundärmarkt und Interessenkonflikte durch die vielfältigen Rollen von JPMorgan. Die Notes sind nicht FDIC-versichert.

The information in this preliminary pricing supplement is not complete and may be changed. This preliminary pricing supplement is not an
offer to sell nor does it seek an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.
Subject to completion dated July 8, 2025
July , 2025
Registration Statement Nos. 333-270004 and 333-270004-01; Rule 424(b)(2)
Pricing supplement to product supplement no. 4-I dated April 13, 2023, the prospectus and prospectus supplement, each dated April 13, 2023, and
the prospectus addendum dated June 3, 2024
JPMorgan Chase Financial Company LLC
Structured Investments
Auto Callable Yield Notes Linked to the Least
Performing of the Common Stock of Broadcom Inc.,
the Common Stock of Moderna, Inc. and the Common
Stock of NVIDIA Corporation due July 20, 2026
Fully and Unconditionally Guaranteed by JPMorgan Chase & Co.
The notes are designed for investors who seek a higher interest rate than the yield on a conventional debt security with the
same maturity issued by us. The notes will pay at least 22.35% per annum interest over the term of the notes, assuming no
automatic call, payable at a rate of at least 1.8625% per month.
The notes will be automatically called if the closing price of one share of each Reference Stock on any Review Date (other
than the final Review Date) is greater than or equal to its Initial Value.
The earliest date on which an automatic call may be initiated is January 15, 2026.
Investors should be willing to accept the risk of losing some or all of their principal and be willing to forgo dividend payments,
in exchange for Interest Payments.
The notes are unsecured and unsubordinated obligations of JPMorgan Chase Financial Company LLC, which we refer to as
JPMorgan Financial, the payment on which is fully and unconditionally guaranteed by JPMorgan Chase & Co. Any
payment on the notes is subject to the credit risk of JPMorgan Financial, as issuer of the notes, and the credit risk
of JPMorgan Chase & Co., as guarantor of the notes.
Payments on the notes are not linked to a basket composed of the Reference Stocks. Payments on the notes are linked to
the performance of each of the Reference Stocks individually, as described below.
Minimum denominations of $1,000 and integral multiples thereof
The notes are expected to price on or about July 15, 2025 and are expected to settle on or about July 18, 2025.
CUSIP: 48136FMR0
Investing in the notes involves a number of risks. See “Risk Factors” beginning on page S-2 of the accompanying
prospectus supplement, Annex A to the accompanying prospectus addendum, “Risk Factors” beginning on page PS-11 of
the accompanying product supplement and “Selected Risk Considerations” beginning on page PS-4 of this pricing
supplement.
Neither the Securities and Exchange Commission (the “SEC”) nor any state securities commission has approved or disapproved of
the notes or passed upon the accuracy or the adequacy of this pricing supplement or the accompanying product supplement,
prospectus supplement, prospectus and prospectus addendum. Any representation to the contrary is a criminal offense.
Price to Public (1)
Fees and Commissions (2)
Proceeds to Issuer
Per note
$1,000
$
$
Total
$
$
$
(1) See “Supplemental Use of Proceeds” in this pricing supplement for information about the components of the price to public of the notes.
(2) J.P. Morgan Securities LLC, which we refer to as JPMS, acting as agent for JPMorgan Financial, will pay all of the selling commissions it
receives from us to other affiliated or unaffiliated dealers. In no event will these selling commissions exceed $15.00 per $1,000 principal
amount note. See “Plan of Distribution (Conflicts of Interest)” in the accompanying product supplement.
If the notes priced today, the estimated value of the notes would be approximately $955.70 per $1,000 principal amount
note. The estimated value of the notes, when the terms of the notes are set, will be provided in the pricing supplement and
will not be less than $920.00 per $1,000 principal amount note. See “The Estimated Value of the Notes” in this pricing
supplement for additional information.
The notes are not bank deposits, are not insured by the Federal Deposit Insurance Corporation or any other governmental agency
and are not obligations of, or guaranteed by, a bank.
Key Terms
Issuer: JPMorgan Chase Financial Company LLC, a direct,
wholly owned finance subsidiary of JPMorgan Chase & Co.
Guarantor: JPMorgan Chase & Co.
Reference Stocks: As specified under “Key Terms Relating
to the Reference Stocks” in this pricing supplement
Interest Payments: If the notes have not been automatically
called, you will receive on each Interest Payment Date for
each $1,000 principal amount note an Interest Payment equal
to at least $18.625 (equivalent to an Interest Rate of at least
22.35% per annum, payable at a rate of at least 1.8625% per
month) (to be provided in the pricing supplement).
Interest Rate: At least 22.35% per annum, payable at a rate
of at least 1.8625% per month (to be provided in the pricing
supplement)
Trigger Value: With respect to each Reference Stock,
60.00% of its Initial Value, as specified under "Key Terms
Relating to the Reference Stocks" in this pricing supplement
Pricing Date: On or about July 15, 2025
Original Issue Date (Settlement Date): On or about July 18,
2025
Review Dates*: January 15, 2026, February 17, 2026, March
16, 2026, April 15, 2026, May 15, 2026, June 15, 2026 and
July 15, 2026 (final Review Date)
Interest Payment Dates*: August 20, 2025, September 18,
2025, October 20, 2025, November 20, 2025, December 18,
2025, January 21, 2026, February 20, 2026, March 19, 2026,
April 20, 2026, May 20, 2026, June 18, 2026 and the Maturity
Date
Maturity Date*: July 20, 2026
Call Settlement Date*: If the notes are automatically called
on any Review Date (other than the final Review Date), the
first Interest Payment Date immediately following that Review
Date
* Subject to postponement in the event of a market disruption event
and as described under “General Terms of Notes Postponement of
a Determination Date Notes Linked to Multiple Underlyings” and
“General Terms of Notes Postponement of a Payment Date” in the
accompanying product supplement
Automatic Call:
If the closing price of one share of each Reference Stock on
any Review Date (other than the final Review Date) is greater
than or equal to its Initial Value, the notes will be
automatically called for a cash payment, for each $1,000
principal amount note, equal to (a) $1,000 plus (b) the Interest
Payment for the Interest Payment Date occurring on the
applicable Call Settlement Date, payable on that Call
Settlement Date. No further payments will be made on the
notes.
Payment at Maturity:
If the notes have not been automatically called and the Final
Value of each Reference Stock is greater than or equal to its
Trigger Value, you will receive a cash payment at maturity, for
each $1,000 principal amount note, equal to (a) $1,000 plus
(b) the Interest Payment applicable to the Maturity Date.
If the notes have not been automatically called and the Final
Value of any Reference Stock is less than its Trigger Value,
your payment at maturity per $1,000 principal amount note, in
addition to the Interest Payment applicable to the Maturity
Date, will be calculated as follows:
$1,000 + ($1,000 × Least Performing Stock Return)
If the notes have not been automatically called and the Final
Value of any Reference Stock is less than its Trigger Value,
you will lose more than 40.00% of your principal amount at
maturity and could lose all of your principal amount at
maturity.
Least Performing Reference Stock: The Reference Stock
with the Least Performing Stock Return
Least Performing Stock Return: The lowest of the Stock
Returns of the Reference Stocks
Stock Return: With respect to each Reference Stock,
(Final Value Initial Value)
Initial Value
Initial Value: With respect to each Reference Stock, the
closing price of one share of that Reference Stock on the
Pricing Date, as specified under “Key Terms Relating to the
Reference Stocks” in this pricing supplement
Final Value: With respect to each Reference Stock, the
closing price of one share of that Reference Stock on the final
Review Date
Stock Adjustment Factor: With respect to each Reference
Stock, the Stock Adjustment Factor is referenced in
determining the closing price of one share of that Reference
Stock and is set equal to 1.0 on the Pricing Date. The Stock
Adjustment Factor of each Reference Stock is subject to
adjustment upon the occurrence of certain corporate events
affecting that Reference Stock. See “The Underlyings —
Reference Stocks Anti-Dilution Adjustments” and “The
Underlyings Reference Stocks Reorganization Events”
in the accompanying product supplement for further
information.
Supplemental Terms of the Notes
Any value of any underlier, and any values derived therefrom, included in this pricing supplement may be corrected, in the event of
manifest error or inconsistency, by amendment of this pricing supplement and the corresponding terms of the notes. Notwithstanding
anything to the contrary in the indenture governing the notes, that amendment will become effective without consent of the holders of
the notes or any other party.
Key Terms Relating to the Reference Stocks
Reference Stock
Bloomberg
Ticker Symbol
Initial Value
Trigger Value
Common stock of Broadcom Inc., par value $0.001 per share
AVGO
$
$
Common stock of Moderna, Inc., par value $0.0001 per share
MRNA
$
$
Common stock of NVIDIA Corporation, par value $0.001 per share
NVDA
$
$
How the Notes Work
Payments in Connection with Review Dates Preceding the Final Review Date
Review Dates Preceding the Final Review Date
Initial
Value
Compare the closing price of one share of each Reference Stock to its Initial Value on each Review Date until the final
Review Date or any earlier automatic call.
The closing price of
one share of each
Reference Stock is
greater than or
equal to its Initial
Value.
Automatic Call
The notes will be automatically called on the applicable Call Settlement Date and you will
receive (a) $1,000 plus (b) the Interest Payment for the Interest Payment Date occurring
on that Call Settlement Date.
No further payments will be made on the notes.
The closing price of
one share of any
Reference Stock is
less than its Initial
Value.
No Automatic Call
The notes will not be automatically called. You will receive an Interest Payment on the
immediately following Interest Payment Date.
Proceed to the next Review Date.
Payment at Maturity If the Notes Have Not Been Automatically Called
Review Dates
Preceding the Final
Review Date
Final Review Date
Payment at Maturity
The notes are not
automatically called.
The Final Value of each Reference Stock is
greater than or equal to its Trigger Value.
You will receive (a) $1,000 plus (b) the
Interest Payment applicable to the
Maturity Date.
Proceed to maturity
The Final Value of any Reference Stock is
less than its Trigger Value.
You will receive, in addition to the Interest
Payment applicable to the Maturity Date:
$1,000 + ($1,000 x Least Performing Stock
Return)
Under these circumstances, you will lose
some or all of your principal amount at
maturity.
Total Interest Payments
The table below illustrates the hypothetical total Interest Payments per $1,000 principal amount note over the term of the notes based
on a hypothetical Interest Rate of 22.35% per annum, depending on how many Interest Payments are made prior to automatic call or
maturity. If the notes have not been automatically called, the hypothetical total Interest Payments per $1,000 principal amount note over
the term of the notes will be equal to the maximum amount shown in the table below. The actual Interest Rate will be provided in the
pricing supplement and will be at least 22.35% per annum.
Number of Interest
Payments
Total Interest Payments
12
$223.500
11
$204.875
10
$186.250
9
$167.625
8
$149.000
7
$130.375
6
$111.750
Hypothetical Payout Examples
The following examples illustrate payments on the notes linked to three hypothetical Reference Stocks, assuming a range of
performances for the hypothetical Least Performing Reference Stock on the Review Dates. Solely for purposes of this section, the
Least Performing Reference Stock with respect to each Review Date is the least performing of the Reference Stocks
determined based on the closing price of one share of each Reference Stock on that Review Date compared with its Initial
Value.
The hypothetical payments set forth below assume the following:
an Initial Value for each Reference Stock of $100.00;
a Trigger Value for each Reference Stock of $60.00 (equal to 60.00% of its hypothetical Initial Value); and
an Interest Rate of 22.35% per annum (payable at a rate of 1.8625% per month).
The hypothetical Initial Value of each Reference Stock of $100.00 has been chosen for illustrative purposes only and may not represent
a likely actual Initial Value of any Reference Stock.
The actual Initial Value of each Reference Stock will be the closing price of one share of that Reference Stock on the Pricing Date and
will be provided in the pricing supplement. For historical data regarding the actual closing prices of one share of each Reference Stock,
please see the historical information set forth under “The Reference Stocks” in this pricing supplement.
Each hypothetical payment set forth below is for illustrative purposes only and may not be the actual payment applicable to a purchaser
of the notes. The numbers appearing in the following examples have been rounded for ease of analysis.
Example 1 Notes are automatically called on the first Review Date.
Date
Closing Price of One
Share of Least
Performing Reference
Stock
First Review Date
$101.00
Notes are automatically called
Total Payment
$1,111.75 (11.175% return)
Because the closing price of one share of each Reference Stock on the first Review Date is greater than or equal to its Initial Value, the
notes will be automatically called for a cash payment, for each $1,000 principal amount note, of $1,018.625 (or $1,000 plus the Interest
Payment applicable to the corresponding Interest Payment Date), payable on the applicable Call Settlement Date. When added to the
Interest Payments received with respect to the prior Interest Payment Dates, the total amount paid, for each $1,000 principal amount
note, is $1,111.75. No further payments will be made on the notes.
Example 2 Notes have NOT been automatically called and the Final Value of the Least Performing Reference
Stock is greater than or equal to its Trigger Value.
Date
Closing Price of One
Share of Least
Performing Reference
Stock
First Review Date
$90.00
Notes NOT automatically called
Second Review Date
$95.00
Notes NOT automatically called
Third through Sixth
Review Dates
Less than Initial Value
Notes NOT automatically called
Final Review Date
$90.00
Final Value of Least Performing Reference Stock is greater than or
equal to its Trigger Value
Total Payment
$1,223.50 (22.35% return)
Because the notes have not been automatically called and the Final Value of the Least Performing Reference Stock is greater than or
equal to its Trigger Value, the payment at maturity, for each $1,000 principal amount note, will be $1,018.625 (or $1,000 plus the
Interest Payment applicable to the Maturity Date). When added to the Interest Payments received with respect to the prior Interest
Payment Dates, the total amount paid, for each $1,000 principal amount note, is $1,223.50.
Example 3 Notes have NOT been automatically called and the Final Value of the Least Performing Reference
Stock is less than its Trigger Value.
Date
Closing Price of One
Share of Least
Performing Reference
Stock
First Review Date
$90.00
Notes NOT automatically called
Second Review Date
$80.00
Notes NOT automatically called
Third through Sixth
Review Dates
Less than Initial Value
Notes NOT automatically called
Final Review Date
$50.00
Final Value of Least Performing Reference Stock is less than its
Trigger Value
Total Payment
$723.50 (-27.65% return)
Because the notes have not been automatically called, the Final Value of the Least Performing Reference Stock is less than its Trigger
Value and the Least Performing Stock Return is -50.00%, the payment at maturity will be $518.625 per $1,000 principal amount note,
calculated as follows:
$1,000 + [$1,000 × (-50.00%)] + $18.625 = $518.625
When added to the Interest Payments received with respect to the prior Interest Payment Dates, the total amount paid, for each $1,000
principal amount note, is $723.50.
The hypothetical returns and hypothetical payments on the notes shown above apply only if you hold the notes for their entire term
or until automatically called. These hypotheticals do not reflect the fees or expenses that would be associated with any sale in the
secondary market. If these fees and expenses were included, the hypothetical returns and hypothetical payments shown above would
likely be lower.
Selected Risk Considerations
An investment in the notes involves significant risks. These risks are explained in more detail in the “Risk Factors” sections of the
accompanying prospectus supplement and product supplement and in Annex A to the accompanying prospectus addendum.
Risks Relating to the Notes Generally
YOUR INVESTMENT IN THE NOTES MAY RESULT IN A LOSS
The notes do not guarantee any return of principal. If the notes have not been automatically called and the Final Value of any
Reference Stock is less than its Trigger Value, you will lose 1% of the principal amount of your notes for every 1% that the Final
Value of the Least Performing Reference Stock is less than its Initial Value. Accordingly, under these circumstances, you will lose
more than 40.00% of your principal amount at maturity and could lose all of your principal amount at maturity.
CREDIT RISKS OF JPMORGAN FINANCIAL AND JPMORGAN CHASE & CO.
Investors are dependent on our and JPMorgan Chase & Co.’s ability to pay all amounts due on the notes. Any actual or potential
change in our or JPMorgan Chase & Co.’s creditworthiness or credit spreads, as determined by the market for taking that credit
risk, is likely to adversely affect the value of the notes. If we and JPMorgan Chase & Co. were to default on our payment
obligations, you may not receive any amounts owed to you under the notes and you could lose your entire investment.
AS A FINANCE SUBSIDIARY, JPMORGAN FINANCIAL HAS NO INDEPENDENT OPERATIONS AND HAS LIMITED ASSETS
As a finance subsidiary of JPMorgan Chase & Co., we have no independent operations beyond the issuance and administration of
our securities and the collection of intercompany obligations. Aside from the initial capital contribution from JPMorgan Chase & Co.,
substantially all of our assets relate to obligations of JPMorgan Chase & Co. to make payments under loans made by us to
JPMorgan Chase & Co. or under other intercompany agreements. As a result, we are dependent upon payments from JPMorgan
Chase & Co. to meet our obligations under the notes. We are not a key operating subsidiary of JPMorgan Chase & Co. and in a
bankruptcy or resolution of JPMorgan Chase & Co. we are not expected to have sufficient resources to meet our obligations in
respect of the notes as they come due. If JPMorgan Chase & Co. does not make payments to us and we are unable to make
payments on the notes, you may have to seek payment under the related guarantee by JPMorgan Chase & Co., and that
guarantee will rank pari passu with all other unsecured and unsubordinated obligations of JPMorgan Chase & Co. For more
information, see the accompanying prospectus addendum.
THE APPRECIATION POTENTIAL OF THE NOTES IS LIMITED TO THE SUM OF THE INTEREST PAYMENTS PAID OVER
THE TERM OF THE NOTES,
regardless of any appreciation of any Reference Stock, which may be significant. You will not participate in any appreciation of any
Reference Stock.
YOU ARE EXPOSED TO THE RISK OF DECLINE IN THE PRICE OF ONE SHARE OF EACH REFERENCE STOCK
Payments on the notes are not linked to a basket composed of the Reference Stocks and are contingent upon the performance of
each individual Reference Stock. Poor performance by any of the Reference Stocks over the term of the notes may result in the
notes not being automatically called on a Review Date, may negatively affect your payment at maturity and will not be offset or
mitigated by positive performance by any other Reference Stock.
YOUR PAYMENT AT MATURITY WILL BE DETERMINED BY THE LEAST PERFORMING REFERENCE STOCK.
THE BENEFIT PROVIDED BY THE TRIGGER VALUE MAY TERMINATE ON THE FINAL REVIEW DATE
If the Final Value of any Reference Stock is less than its Trigger Value and the notes have not been automatically called, the
benefit provided by the Trigger Value will terminate and you will be fully exposed to any depreciation of the Least Performing
Reference Stock.
THE AUTOMATIC CALL FEATURE MAY FORCE A POTENTIAL EARLY EXIT
If your notes are automatically called, the term of the notes may be reduced to as short as approximately six months and you will
not receive any Interest Payments after the applicable Call Settlement Date. There is no guarantee that you would be able to
reinvest the proceeds from an investment in the notes at a comparable return and/or with a comparable interest rate for a similar
level of risk. Even in cases where the notes are called before maturity, you are not entitled to any fees and commissions described
on the front cover of this pricing supplement.
YOU WILL NOT RECEIVE DIVIDENDS ON ANY REFERENCE STOCK OR HAVE ANY RIGHTS WITH RESPECT TO ANY
REFERENCE STOCK.
THE RISK OF THE CLOSING PRICE OF ONE SHARE OF A REFERENCE STOCK FALLING BELOW ITS TRIGGER VALUE IS
GREATER IF THE PRICE OF ONE SHARE OF THAT REFERENCE STOCK IS VOLATILE.
LACK OF LIQUIDITY
The notes will not be listed on any securities exchange. Accordingly, the price at which you may be able to trade your notes is likely
to depend on the price, if any, at which JPMS is willing to buy the notes. You may not be able to sell your notes. The notes are not
designed to be short-term trading instruments. Accordingly, you should be able and willing to hold your notes to maturity.
THE FINAL TERMS AND VALUATION OF THE NOTES WILL BE PROVIDED IN THE PRICING SUPPLEMENT
You should consider your potential investment in the notes based on the minimums for the estimated value of the notes and the
Interest Rate.
Risks Relating to Conflicts of Interest
POTENTIAL CONFLICTS
We and our affiliates play a variety of roles in connection with the notes. In performing these duties, our and JPMorgan Chase &
Co.’s economic interests are potentially adverse to your interests as an investor in the notes. It is possible that hedging or trading
activities of ours or our affiliates in connection with the notes could result in substantial returns for us or our affiliates while the
value of the notes declines. Please refer to “Risk Factors — Risks Relating to Conflicts of Interest” in the accompanying product
supplement.
Risks Relating to the Estimated Value and Secondary Market Prices of the Notes
THE ESTIMATED VALUE OF THE NOTES WILL BE LOWER THAN THE ORIGINAL ISSUE PRICE (PRICE TO PUBLIC) OF
THE NOTES
The estimated value of the notes is only an estimate determined by reference to several factors. The original issue price of the
notes will exceed the estimated value of the notes because costs associated with selling, structuring and hedging the notes are
included in the original issue price of the notes. These costs include the selling commissions, the projected profits, if any, that our
affiliates expect to realize for assuming risks inherent in hedging our obligations under the notes and the estimated cost of hedging
our obligations under the notes. See “The Estimated Value of the Notes” in this pricing supplement.
THE ESTIMATED VALUE OF THE NOTES DOES NOT REPRESENT FUTURE VALUES OF THE NOTES AND MAY DIFFER
FROM OTHERS’ ESTIMATES —
See “The Estimated Value of the Notes” in this pricing supplement.
THE ESTIMATED VALUE OF THE NOTES IS DERIVED BY REFERENCE TO AN INTERNAL FUNDING RATE
The internal funding rate used in the determination of the estimated value of the notes may differ from the market-implied funding
rate for vanilla fixed income instruments of a similar maturity issued by JPMorgan Chase & Co. or its affiliates. Any difference may
be based on, among other things, our and our affiliates’ view of the funding value of the notes as well as the higher issuance,
operational and ongoing liability management costs of the notes in comparison to those costs for the conventional fixed income
instruments of JPMorgan Chase & Co. This internal funding rate is based on certain market inputs and assumptions, which may
prove to be incorrect, and is intended to approximate the prevailing market replacement funding rate for the notes. The use of an
internal funding rate and any potential changes to that rate may have an adverse effect on the terms of the notes and any
secondary market prices of the notes. See “The Estimated Value of the Notes” in this pricing supplement.
THE VALUE OF THE NOTES AS PUBLISHED BY JPMS (AND WHICH MAY BE REFLECTED ON CUSTOMER ACCOUNT
STATEMENTS) MAY BE HIGHER THAN THE THEN-CURRENT ESTIMATED VALUE OF THE NOTES FOR A LIMITED TIME
PERIOD
We generally expect that some of the costs included in the original issue price of the notes will be partially paid back to you in
connection with any repurchases of your notes by JPMS in an amount that will decline to zero over an initial predetermined period.
See “Secondary Market Prices of the Notes” in this pricing supplement for additional information relating to this initial period.
Accordingly, the estimated value of your notes during this initial period may be lower than the value of the notes as published by
JPMS (and which may be shown on your customer account statements).
SECONDARY MARKET PRICES OF THE NOTES WILL LIKELY BE LOWER THAN THE ORIGINAL ISSUE PRICE OF THE
NOTES
Any secondary market prices of the notes will likely be lower than the original issue price of the notes because, among other
things, secondary market prices take into account our internal secondary market funding rates for structured debt issuances and,
also, because secondary market prices may exclude selling commissions, projected hedging profits, if any, and estimated hedging
costs that are included in the original issue price of the notes. As a result, the price, if any, at which JPMS will be willing to buy the
notes from you in secondary market transactions, if at all, is likely to be lower than the original issue price. Any sale by you prior to
the Maturity Date could result in a substantial loss to you.
SECONDARY MARKET PRICES OF THE NOTES WILL BE IMPACTED BY MANY ECONOMIC AND MARKET FACTORS
The secondary market price of the notes during their term will be impacted by a number of economic and market factors, which
may either offset or magnify each other, aside from the selling commissions, projected hedging profits, if any, estimated hedging
costs and the prices of one share of the Reference Stocks. Additionally, independent pricing vendors and/or third party broker-
dealers may publish a price for the notes, which may also be reflected on customer account statements. This price may be different
(higher or lower) than the price of the notes, if any, at which JPMS may be willing to purchase your notes in the secondary market.
See “Risk Factors — Risks Relating to the Estimated Value and Secondary Market Prices of the Notes Secondary market prices
of the notes will be impacted by many economic and market factors” in the accompanying product supplement.
Risks Relating to the Reference Stocks
NO AFFILIATION WITH ANY REFERENCE STOCK ISSUER
We have not independently verified any of the information about any Reference Stock issuer contained in this pricing supplement.
You should undertake your own investigation into each Reference Stock and its issuer. We are not responsible for any Reference
Stock issuer’s public disclosure of information, whether contained in SEC filings or otherwise.
THE ANTI-DILUTION PROTECTION FOR EACH REFERENCE STOCK IS LIMITED AND MAY BE DISCRETIONARY
The calculation agent will not make an adjustment in response to all events that could affect a Reference Stock. The calculation
agent may make adjustments in response to events that are not described in the accompanying product supplement to account for
any diluting or concentrative effect, but the calculation agent is under no obligation to do so or to consider your interests as a
holder of the notes in making these determinations.
The Reference Stocks
All information contained herein on the Reference Stocks and on the Reference Stock issuers is derived from publicly available
sources, without independent verification. Each Reference Stock is registered under the Securities Exchange Act of 1934, as amended,
which we refer to as the Exchange Act, and is listed on the exchange provided in the table below, which we refer to as the relevant
exchange for purposes of that Reference Stock in the accompanying product supplement. Information provided to or filed with the SEC
by a Reference Stock issuer pursuant to the Exchange Act can be located by reference to the SEC file number provided in the table
below, and can be accessed through www.sec.gov. We do not make any representation that these publicly available documents are
accurate or complete. We obtained the closing prices below from the Bloomberg Professional® service (“Bloomberg”) without
independent verification.
Reference Stock
Bloomberg
Ticker
Symbol
Relevant Exchange
SEC File Number
Closing Price on
July 7, 2025
Common stock of Broadcom Inc., par value
$0.001 per share
AVGO
The Nasdaq Stock
Market
001-38449
$274.18
Common stock of Moderna, Inc., par value
$0.0001 per share
MRNA
The Nasdaq Stock
Market
001-38753
$29.90
Common stock of NVIDIA Corporation, par value
$0.001 per share
NVDA
The Nasdaq Stock
Market
000-23985
$158.24
According to publicly available filings of the relevant Reference Stock issuer with the SEC:
Broadcom designs, develops and supplies a range of semiconductor and infrastructure software solutions.
Moderna is a biotechnology company, developing medicines based on messenger RNA, including therapeutics and vaccines
for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases, independently and with strategic
collaborators.
NVIDIA is a full-stack computing infrastructure company with data-center-scale offerings whose full-stack includes the CUDA
programming model that runs on all of its graphics processing units (GPUs), as well as domain-specific software libraries,
software development kits and Application Programming Interfaces and whose data-center-scale offerings include compute
and networking solutions that can scale to tens of thousands of GPU-accelerated servers interconnected to function as a
single giant computer.
Historical Information
The following graphs set forth the historical performance of each Reference Stock based on the weekly historical closing prices of one
share of that Reference Stock from January 3, 2020 through July 3, 2025. The closing prices above and below may have been adjusted
by Bloomberg for corporate actions, such as stock splits, public offerings, mergers and acquisitions, spin-offs, delistings and
bankruptcy.
The historical closing prices of one share of each Reference Stock should not be taken as an indication of future performance, and no
assurance can be given as to the closing price of one share of any Reference Stock on the Pricing Date or any Review Date. There can
be no assurance that the performance of the Reference Stocks will result in the return of any of your principal amount.
Historical Performance of the Common stock of Broadcom Inc.
Source: Bloomberg
Historical Performance of the Common stock of Moderna, Inc.
Source: Bloomberg
Historical Performance of the Common stock of NVIDIA Corporation
Source: Bloomberg
Tax Treatment
You should review carefully the section entitled “Material U.S. Federal Income Tax Consequences” in the accompanying product
supplement no. 4-I. Based on the advice of Davis Polk & Wardwell LLP, our special tax counsel, and on current market conditions, in
determining our reporting responsibilities we intend to treat the notes for U.S. federal income tax purposes as units each comprising: (x)
a cash-settled Put Option written by you that is terminated if an automatic call occurs and that, if not terminated, in circumstances
where the payment due at maturity is less than $1,000 (excluding accrued but unpaid interest), requires you to pay us an amount equal
to that difference and (y) a Deposit of $1,000 per $1,000 principal amount note to secure your potential obligation under the Put Option,
as more fully described in “Material U.S. Federal Income Tax Consequences — Tax Consequences to U.S. Holders Notes Treated
as Units Each Comprising a Put Option and a Deposit” in the accompanying product supplement, and in particular in the subsection
thereof entitled “— Notes with a Term of More than One Year.” By purchasing the notes, you agree (in the absence of an
administrative determination or judicial ruling to the contrary) to follow this treatment and the allocation described in the following
paragraph. However, there are other reasonable treatments that the IRS or a court may adopt, in which case the timing and character
of any income or loss on the notes could be materially and adversely affected. In addition, in 2007 Treasury and the IRS released a
notice requesting comments on the U.S. federal income tax treatment of “prepaid forward contracts” and similar instruments. The
notice focuses on a number of issues, the most relevant of which for investors in the notes are the character of income or loss
(including whether the Put Premium might be currently included as ordinary income) and the degree, if any, to which income realized by
non-U.S. investors should be subject to withholding tax. While it is not clear whether the notes would be viewed as similar to the typical
prepaid forward contract described in the notice, it is possible that any Treasury regulations or other guidance promulgated after
consideration of these issues could materially and adversely affect the tax consequences of an investment in the notes, possibly with
retroactive effect.
In determining our reporting responsibilities, we intend to treat a portion of each Interest Payment equal to approximately 4.20% per
annum times the amount of the Deposit times the number of days in the applicable period divided by 365 as interest on the Deposit (so
that the amount allocated as interest on the Deposit will vary from Interest Payment to Interest Payment depending on the number of
days in the applicable period) and the remainder of each Interest Payment as Put Premium. Assuming that the treatment of the notes
as units each comprising a Put Option and a Deposit is respected, amounts treated as interest on the Deposit will be taxed as ordinary
income, while the Put Premium will not be taken into account prior to sale or settlement.
Section 871(m) of the Code and Treasury regulations promulgated thereunder (“Section 871(m)”) generally impose a 30% withholding
tax (unless an income tax treaty applies) on dividend equivalents paid or deemed paid to Non-U.S. Holders with respect to certain
financial instruments linked to U.S. equities or indices that include U.S. equities. Section 871(m) provides certain exceptions to this
withholding regime, including for instruments linked to certain broad-based indices that meet requirements set forth in the applicable
Treasury regulations. Additionally, a recent IRS notice excludes from the scope of Section 871(m) instruments issued prior to January
1, 2027 that do not have a delta of one with respect to underlying securities that could pay U.S.-source dividends for U.S. federal
income tax purposes (each an “Underlying Security”). Based on certain determinations made by us, we expect that Section 871(m) will
not apply to the notes with regard to Non-U.S. Holders. Our determination is not binding on the IRS, and the IRS may disagree with
this determination. Section 871(m) is complex and its application may depend on your particular circumstances, including whether you
enter into other transactions with respect to an Underlying Security. If necessary, further information regarding the potential application
of Section 871(m) will be provided in the pricing supplement for the notes. You should consult your tax adviser regarding the potential
application of Section 871(m) to the notes.
The discussions above and in the accompanying product supplement do not address the consequences to taxpayers subject to special
tax accounting rules under Section 451(b) of the Code. You should consult your tax adviser regarding all aspects of the U.S. federal
income tax consequences of an investment in the notes, including possible alternative treatments and the issues presented by the 2007
notice. Purchasers who are not initial purchasers of notes at the issue price should also consult their tax advisers with respect to the
tax consequences of an investment in the notes, including possible alternative treatments, as well as the allocation of the purchase
price of the notes between the Deposit and the Put Option.
The Estimated Value of the Notes
The estimated value of the notes set forth on the cover of this pricing supplement is equal to the sum of the values of the following
hypothetical components: (1) a fixed-income debt component with the same maturity as the notes, valued using the internal funding
rate described below, and (2) the derivative or derivatives underlying the economic terms of the notes. The estimated value of the notes
does not represent a minimum price at which JPMS would be willing to buy your notes in any secondary market (if any exists) at any
time. The internal funding rate used in the determination of the estimated value of the notes may differ from the market-implied funding
rate for vanilla fixed income instruments of a similar maturity issued by JPMorgan Chase & Co. or its affiliates. Any difference may be
based on, among other things, our and our affiliates’ view of the funding value of the notes as well as the higher issuance, operational
and ongoing liability management costs of the notes in comparison to those costs for the conventional fixed income instruments of
JPMorgan Chase & Co. This internal funding rate is based on certain market inputs and assumptions, which may prove to be incorrect,
and is intended to approximate the prevailing market replacement funding rate for the notes. The use of an internal funding rate and
any potential changes to that rate may have an adverse effect on the terms of the notes and any secondary market prices of the notes.
For additional information, see “Selected Risk Considerations — Risks Relating to the Estimated Value and Secondary Market Prices of
the Notes The Estimated Value of the Notes Is Derived by Reference to an Internal Funding Rate” in this pricing supplement.
The value of the derivative or derivatives underlying the economic terms of the notes is derived from internal pricing models of our
affiliates. These models are dependent on inputs such as the traded market prices of comparable derivative instruments and on various
other inputs, some of which are market-observable, and which can include volatility, dividend rates, interest rates and other factors, as
well as assumptions about future market events and/or environments. Accordingly, the estimated value of the notes is determined when
the terms of the notes are set based on market conditions and other relevant factors and assumptions existing at that time.
The estimated value of the notes does not represent future values of the notes and may differ from others’ estimates. Different pricing
models and assumptions could provide valuations for the notes that are greater than or less than the estimated value of the notes. In
addition, market conditions and other relevant factors in the future may change, and any assumptions may prove to be incorrect. On
future dates, the value of the notes could change significantly based on, among other things, changes in market conditions, our or
JPMorgan Chase & Co.’s creditworthiness, interest rate movements and other relevant factors, which may impact the price, if any, at
which JPMS would be willing to buy notes from you in secondary market transactions.
The estimated value of the notes will be lower than the original issue price of the notes because costs associated with selling,
structuring and hedging the notes are included in the original issue price of the notes. These costs include the selling commissions paid
to JPMS and other affiliated or unaffiliated dealers, the projected profits, if any, that our affiliates expect to realize for assuming risks
inherent in hedging our obligations under the notes and the estimated cost of hedging our obligations under the notes. Because
hedging our obligations entails risk and may be influenced by market forces beyond our control, this hedging may result in a profit that
is more or less than expected, or it may result in a loss. A portion of the profits, if any, realized in hedging our obligations under the
notes may be allowed to other affiliated or unaffiliated dealers, and we or one or more of our affiliates will retain any remaining hedging
profits. See “Selected Risk Considerations — Risks Relating to the Estimated Value and Secondary Market Prices of the Notes The
Estimated Value of the Notes Will Be Lower Than the Original Issue Price (Price to Public) of the Notes” in this pricing supplement.
Secondary Market Prices of the Notes
For information about factors that will impact any secondary market prices of the notes, see “Risk Factors — Risks Relating to the
Estimated Value and Secondary Market Prices of the Notes Secondary market prices of the notes will be impacted by many
economic and market factors” in the accompanying product supplement. In addition, we generally expect that some of the costs
included in the original issue price of the notes will be partially paid back to you in connection with any repurchases of your notes by
JPMS in an amount that will decline to zero over an initial predetermined period. These costs can include selling commissions,
projected hedging profits, if any, and, in some circumstances, estimated hedging costs and our internal secondary market funding rates
for structured debt issuances. This initial predetermined time period is intended to be the shorter of six months and one-half of the
stated term of the notes. The length of any such initial period reflects the structure of the notes, whether our affiliates expect to earn a
profit in connection with our hedging activities, the estimated costs of hedging the notes and when these costs are incurred, as
determined by our affiliates. See “Selected Risk Considerations — Risks Relating to the Estimated Value and Secondary Market Prices
of the Notes The Value of the Notes as Published by JPMS (and Which May Be Reflected on Customer Account Statements) May
Be Higher Than the Then-Current Estimated Value of the Notes for a Limited Time Period” in this pricing supplement.
Supplemental Use of Proceeds
The notes are offered to meet investor demand for products that reflect the risk-return profile and market exposure provided by the
notes. See “How the Notes Work” and “Hypothetical Payout Examples” in this pricing supplement for an illustration of the risk-return
profile of the notes and “The Reference Stocks” in this pricing supplement for a description of the market exposure provided by the
notes.
The original issue price of the notes is equal to the estimated value of the notes plus the selling commissions paid to JPMS and other
affiliated or unaffiliated dealers, plus (minus) the projected profits (losses) that our affiliates expect to realize for assuming risks inherent
in hedging our obligations under the notes, plus the estimated cost of hedging our obligations under the notes.
Additional Terms Specific to the Notes
You may revoke your offer to purchase the notes at any time prior to the time at which we accept such offer by notifying the applicable
agent. We reserve the right to change the terms of, or reject any offer to purchase, the notes prior to their issuance. In the event of any
changes to the terms of the notes, we will notify you and you will be asked to accept such changes in connection with your purchase.
You may also choose to reject such changes, in which case we may reject your offer to purchase.
You should read this pricing supplement together with the accompanying prospectus, as supplemented by the accompanying
prospectus supplement relating to our Series A medium-term notes of which these notes are a part, the accompanying prospectus
addendum and the more detailed information contained in the accompanying product supplement. This pricing supplement, together
with the documents listed below, contains the terms of the notes and supersedes all other prior or contemporaneous oral statements as
well as any other written materials including preliminary or indicative pricing terms, correspondence, trade ideas, structures for
implementation, sample structures, fact sheets, brochures or other educational materials of ours. You should carefully consider, among
other things, the matters set forth in the “Risk Factors” sections of the accompanying prospectus supplement and the accompanying
product supplement and in Annex A to the accompanying prospectus addendum, as the notes involve risks not associated with
conventional debt securities. We urge you to consult your investment, legal, tax, accounting and other advisers before you invest in the
notes.
You may access these documents on the SEC website at www.sec.gov as follows (or if such address has changed, by
reviewing our filings for the relevant date on the SEC website):
Product supplement no. 4-I dated April 13, 2023:
http://www.sec.gov/Archives/edgar/data/19617/000121390023029539/ea152803_424b2.pdf
Prospectus supplement and prospectus, each dated April 13, 2023:
http://www.sec.gov/Archives/edgar/data/19617/000095010323005751/crt_dp192097-424b2.pdf
Prospectus addendum dated June 3, 2024:
http://www.sec.gov/Archives/edgar/data/1665650/000095010324007599/dp211753_424b3.htm
Our Central Index Key, or CIK, on the SEC website is 1665650, and JPMorgan Chase & Co.’s CIK is 19617. As used in this pricing
supplement, “we,” “us” and “our” refer to JPMorgan Financial.

FAQ

What coupon rate do the JPMorgan Auto Callable Yield Notes pay?

The notes pay at least 22.35% per annum, credited monthly at a minimum rate of 1.8625%.

When can the notes be automatically called?

Starting January 15, 2026, the notes are called on any Review Date when each reference stock closes at or above its Initial Value.

How can investors lose principal on these notes?

If the notes are not called and any stock closes below 60% of its Initial Value on the final Review Date, repayment is reduced by that stock’s percentage loss.

What is the maturity date of the notes?

The notes mature on July 20, 2026, unless called earlier.

Which stocks underlie the notes?

Broadcom Inc. (AVGO), Moderna Inc. (MRNA) and NVIDIA Corp. (NVDA).

What is the estimated value versus the issue price?

If priced today, the estimated value is $955.70 per $1,000 note, below the $1,000 issue price; final estimated value will not be less than $920.
Inverse VIX S/T Futs ETNs due Mar22,2045

NYSE:VYLD

VYLD Rankings

VYLD Latest News

VYLD Latest SEC Filings

VYLD Stock Data

4.00M
National Commercial Banks
NEW YORK